![PDF] Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy | Semantic Scholar PDF] Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/aaa2aa01bedce63001c5b101b31c008efbb98bf2/3-Table1-1.png)
PDF] Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy | Semantic Scholar
![Focal abnormalities in idiopathic generalized epilepsy: A critical review of the literature - Seneviratne - 2014 - Epilepsia - Wiley Online Library Focal abnormalities in idiopathic generalized epilepsy: A critical review of the literature - Seneviratne - 2014 - Epilepsia - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/c0036032-5790-40c7-a4c6-bf7527a74cc2/epi.2014.55.issue-8.cover.jpg?trick=1682202389581)
Focal abnormalities in idiopathic generalized epilepsy: A critical review of the literature - Seneviratne - 2014 - Epilepsia - Wiley Online Library
![Characteristics of widely used third generation antiepileptic drugs... | Download Scientific Diagram Characteristics of widely used third generation antiepileptic drugs... | Download Scientific Diagram](https://www.researchgate.net/publication/260445153/figure/fig1/AS:601664801214505@1520459475772/Characteristics-of-widely-used-third-generation-antiepileptic-drugs-for-the-treatment.png)
Characteristics of widely used third generation antiepileptic drugs... | Download Scientific Diagram
![The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial - The Lancet The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial - The Lancet](https://www.thelancet.com/cms/attachment/1d0546dc-c3e6-4911-98cd-f06f2aec1f70/gr1.gif)